We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
1. Name and Address of Reporting Person * GOLDSTEIN JOSEPH L | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 6/8/2020 | M(1) | 3000 | A | $413.33 | 9643 | D | |||
Common Stock | 6/8/2020 | M(1) | 3000 | A | $413.33 | 12643 | D | |||
Common Stock | 6/8/2020 | M(1) | 4838 | A | $413.33 | 17481 | D | |||
Common Stock | 6/8/2020 | S(1) | 100 | D | $580.65 | 17381 | D | |||
Common Stock | 6/8/2020 | S(1) | 200 | D | $582.31 (2) | 17181 | D | |||
Common Stock | 6/8/2020 | S(1) | 1175 | D | $583.67 (3) | 16006 | D | |||
Common Stock | 6/8/2020 | S(1) | 200 | D | $585.58 (4) | 15806 | D | |||
Common Stock | 6/8/2020 | S(1) | 300 | D | $587.2 (5) | 15506 | D | |||
Common Stock | 6/8/2020 | S(1) | 3200 | D | $587.88 (6) | 12306 | D | |||
Common Stock | 6/8/2020 | S(1) | 200 | D | $589.87 (7) | 12106 | D | |||
Common Stock | 6/8/2020 | S(1) | 100 | D | $590.47 | 12006 | D | |||
Common Stock | 6/8/2020 | S(1) | 60 | D | $592.46 | 11946 | D | |||
Common Stock | 6/8/2020 | S(1) | 700 | D | $595.31 (8) | 11246 | D | |||
Common Stock | 6/8/2020 | S(1) | 1111 | D | $596.47 (9) | 10135 | D | |||
Common Stock | 6/8/2020 | S(1) | 771 | D | $597.51 (10) | 9364 | D | |||
Common Stock | 6/8/2020 | S(1) | 200 | D | $598.07 | 9164 | D | |||
Common Stock | 6/8/2020 | S(1) | 200 | D | $600.12 (11) | 8964 | D | |||
Common Stock | 6/8/2020 | S(1) | 400 | D | $601.29 (12) | 8564 | D | |||
Common Stock | 6/8/2020 | S(1) | 1196 | D | $602.7 (13) | 7368 | D | |||
Common Stock | 6/8/2020 | S(1) | 525 | D | $603.82 (14) | 6843 | D | |||
Common Stock | 6/8/2020 | S(1) | 200 | D | $604.49 (15) | 6643 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Non-Qualified Stock Option (right to buy) | $413.33 | 6/8/2020 | M (1) | 3000 | (16) | 1/2/2025 | Common Stock | 3000 | $0.0 | 7838 | D | ||||
Non-Qualified Stock Option (right to buy) | $413.33 | 6/8/2020 | M (1) | 3000 | (16) | 1/2/2025 | Common Stock | 3000 | $0.0 | 4838 | D | ||||
Non-Qualified Stock Option (right to buy) | $413.33 | 6/8/2020 | M (1) | 4838 | (16) | 1/2/2025 | Common Stock | 4838 | $0.0 | 0 | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
GOLDSTEIN JOSEPH L 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 | X |
Signatures | ||
/s/**Joseph L. Goldstein | 6/9/2020 | |
**Signature of Reporting Person | Date |
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions